drugset / Trial / NCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2024-07-15
- Completion
- 2024-08-12
Outcome
Met primary endpoint
registry analysis (superiority test); 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD; p <0.0001 NCT05564039 ↗
registry LS Mean difference (Final Values) -0.90 (95% CI -1.10 to -0.69) NCT05564039 ↗
Publications
- Violante-Ortiz R, Rose L, Sharma P, Gomez Valderas E, Chivukula KK, Kwan AY. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Res Care. 2026 Mar 30;14(2):e005711. doi: 10.1136/bmjdrc-2025-005711.
- Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Ann Intern Med. 2025 May;178(5):609-619. doi: 10.7326/ANNALS-24-03849. Epub 2025 Apr 4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 4.5 mg | Subcutaneous |
| Subject | Tirzepatide | Peptide | 15 mg | Subcutaneous |